Sign Up Now For
Our FREE E-mail Newsletter

In each issue of HEALTHbeat:

  • Get trusted advice from the doctors at Harvard Medical School
  • Learn tips for living a healthy lifestyle
  • Stay up-to-date on the latest developments in health
  • Receive special offers on health books and reports
  • Plus, receive your FREE Bonus Report, Living to 100: What's the secret?

[ Maybe Later ] [ No Thanks ]

Check out these newly released Special Health Reports from Harvard Medical School
Learn How

New Releases

You can't buy good health but you can buy good health information. Check out these newly released Special Health Reports from Harvard Medical School:

New technologies help determine if cognitive impairment will lead to Alzheimer’s

With nearly 10 million baby boomers at risk for developing Alzheimer’s disease, researchers are taking a closer look at a condition known as mild cognitive impairment. This is a state between the normal forgetfulness that comes with aging and the more pronounced thinking deficits of dementia. Mild cognitive impairment often progresses to Alzheimer’s disease, but some people remain stable and others recover. New technology is improving the ability to determine who might fall into each category, reports the April 2008 issue of the Harvard Mental Health Letter. These developments are promising because they are occurring just as the first disease-modifying drugs for Alzheimer’s have reached late-stage clinical testing.

One technology, fluorodeoxyglucose positron emission tomography (FDG-PET), measures blood glucose metabolism in the cerebral cortex. Diminished glucose uptake suggests that neurons are not as active. Clinicians can also measure brain volume changes with volumetric MRI to detect shrinkage, which is typical in Alzheimer’s. These techniques are likely to prove most useful when combined with detection of newly discovered proteins believed to be the first signs of Alzheimer’s.

If one of these technologies—or a combination—can reliably predict which people with cognitive impairment are likely to progress to Alzheimer’s, scientists might be able to determine who should get the disease-modifying medications now in development. And they might be able to predict which healthy people are most likely to get mild cognitive impairment, and try to prevent it.

The technologies and medications needed to predict and prevent mild cognitive impairment and Alzheimer’s are still in the early stages of development, but the Harvard Mental Health Letter says that this research will almost certainly lead to better treatments.

Also in this issue of the Harvard Mental Health Letter

  • Mild cognitive impairment
  • Treating preschoolers with psychiatric disorders
  • Getting help for post-combat mental health problems
  • In Brief: Asthma may increase risk of anxiety and depression
  • In Brief: Metformin and lifestyle changes help people taking antipsychotics lose weight
  • Questions & Answers
  • References for “Getting help for post-combat mental health problems”
  • References for “Mild cognitive impairment”
  • References for “Treating preschoolers with psychiatric disorders”

More Harvard Health News »

About Harvard Health Publications

Harvard Health Publications publishes four monthly newsletters--Harvard Health Letter, Harvard Women's Health Watch, Harvard Men's Health Watch, and Harvard Heart Letter--as well as more than 50 special health reports and books drawing on the expertise of the 8,000 faculty physicians at Harvard Medical School and its world-famous affiliated hospitals.